Radius Pharmaceuticals, Inc.
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Polymorphic Forms of RAD1901-2HCL (US 11,708,318) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Polymorphic Forms of RAD1901-2HCL (US 10,385,008) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Selective Androgen Receptor Modulators (US 9,133,182) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Methods for Treating Cancer (US 11,819,480) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,920,044 | Selective Androgen Receptor Modulators In force · High confidence | In force | High confidence | |
| US 8,933,130 | Treatment of vasomotor symptoms with selective estrogen receptor modulators In force · High confidence | In force | High confidence | |
| US 9,133,182 | Selective Androgen Receptor Modulators In force · High confidence | In force | High confidence | |
| US 11,413,258 | Methods for Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 12,263,141 | Treating Y537S Mutant Breast Cancer with RAD1901 and mTOR inhibitor In force · Medium confidence | In force | Medium confidence | |
| US 12,582,617 | Methods for Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 11,819,480 | Methods for Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 10,385,008 | Polymorphic Forms of RAD1901-2HCL In force · High confidence | In force | High confidence | |
| US 10,745,343 | Polymorphic Forms of RAD1901-2HCL In force · High confidence | In force | High confidence | |
| US 11,148,996 | Polymorphic Forms of RAD1901-2HCL In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 18: 10 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 15 abandoned